<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954354</url>
  </required_header>
  <id_info>
    <org_study_id>1601T0831</org_study_id>
    <nct_id>NCT02954354</nct_id>
  </id_info>
  <brief_title>A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza</brief_title>
  <acronym>CAPSTONE 1</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of a single, oral dose of
      baloxavir marboxil compared with placebo by measuring the time to alleviation of symptoms in
      patients with uncomplicated influenza virus infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 8, 2016</start_date>
  <completion_date type="Actual">April 24, 2017</completion_date>
  <primary_completion_date type="Actual">April 4, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Alleviation of Symptoms in Participants Randomized to Baloxavir or Placebo</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours.
Time to alleviation of symptoms was analyzed using the Kaplan-Meier (KM) method; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Alleviation of Symptoms in Adults Randomized to Baloxavir or Oseltamivir</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours.
Time to alleviation of symptoms was analyzed using the Kaplan-Meier(KM) method; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Positive Influenza Virus Titer at Each Time Point in Participants Randomized to Baloxavir or Placebo</measure>
    <time_frame>Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
    <description>Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6 and 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Positive Influenza Virus Titer at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</measure>
    <time_frame>Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
    <description>Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6 and 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point in Participants Randomized to Baloxavir or Placebo</measure>
    <time_frame>Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
    <description>Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) among those assessed measured by reverse transcription polymerase chain reaction (RT-PCR) on Days 2, 3, 4, 5, 6 and 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</measure>
    <time_frame>Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
    <description>Influenza virus RNA was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) among those assessed measured by reverse transcription polymerase chain reaction (RT-PCR) on Days 2, 3, 4, 5, 6 and 9.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Virus Titer at Each Time Point in Participants Randomized to Baloxavir or Placebo</measure>
    <time_frame>Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
    <description>Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods.
If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Virus Titer at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</measure>
    <time_frame>Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
    <description>Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods.
If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Virus RNA (RT-PCR) at Each Time Point in Participants Randomized to Baloxavir or Placebo</measure>
    <time_frame>Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
    <description>Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA is measured by reverse transcription polymerase chain reaction (RT-PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Virus RNA (RT-PCR) at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</measure>
    <time_frame>Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
    <description>Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA was measured by reverse transcription polymerase chain reaction (RT-PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Participants Randomized to Baloxavir or Placebo</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Adults Randomized to Baloxavir or Oseltamivir</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) Adjusted by Baseline of Influenza Virus RNA in Participants Randomized to Baloxavir or Placebo</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) Adjusted by Baseline of Influenza Virus RNA in Adults Randomized to Baloxavir or Oseltamivir</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cessation of Viral Shedding Determined by Virus Titer in Participants Randomized to Baloxavir or Placebo</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀[TCID₅₀/mL]). The median and 95% confidence interval (CI) for time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cessation of Viral Shedding Determined by Virus Titer in Adults Randomized to Baloxavir or Oseltamivir</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀[TCID₅₀/mL]). The time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cessation of Viral Shedding Determined by Virus RNA in Participants Randomized to Baloxavir or Placebo</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR.
Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cessation of Viral Shedding Determined by Virus RNA in Adults Randomized to Baloxavir or Oseltamivir</measure>
    <time_frame>Day 1 to Day 9</time_frame>
    <description>Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR.
Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Whose Symptoms Were Alleviated at Each Time Point in Participants Randomized to Baloxavir or Placebo</measure>
    <time_frame>12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment</time_frame>
    <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Alleviation of symptoms was defined as all seven influenza-related symptoms assessed by the participant as absent (0) or mild (1) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Whose Symptoms Were Alleviated at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</measure>
    <time_frame>12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment</time_frame>
    <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Alleviation of symptoms was defined as all seven influenza-related symptoms assessed by the participant as absent (0) or mild (1) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Alleviation of the Four Systemic Symptoms in Participants Randomized to Baloxavir or Placebo</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of the 4 systemic symptoms was defined as the time between the initiation of the study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.
Time to alleviation of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Alleviation of the Four Systemic Symptoms in Adults Randomized to Baloxavir or Oseltamivir</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of the 4 systemic symptoms was defined as the time between the initiation of the study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.
Time to alleviation of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Alleviation of the Three Respiratory Symptoms in Participants Randomized to Baloxavir or Placebo</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat and nasal congestion) were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours.
Time to alleviation of the 3 respiratory symptoms was analyzed using the KM method; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Alleviation of the Three Respiratory Symptoms in Adults Randomized to Baloxavir or Oseltamivir</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat and nasal congestion) were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours.
Time to alleviation of the 3 respiratory symptoms was analyzed using the KM method; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Composite Symptom Score at Each Time Point in Participants Randomized to Baloxavir or Placebo</measure>
    <time_frame>Day 1 pretreatment (Baseline) and 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment.</time_frame>
    <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant, and ranges from 0 to 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Composite Symptom Score at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</measure>
    <time_frame>Day 1 pretreatment (Baseline) and 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment.</time_frame>
    <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant, and ranges from 0 to 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Fever in Participants Randomized to Baloxavir or Placebo</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours.
Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Resolution of Fever in Adults Randomized to Baloxavir or Oseltamivir</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours.
Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Normal Temperature at Each Time Point in Participants Randomized to Baloxavir or Placebo</measure>
    <time_frame>12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment</time_frame>
    <description>Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Normal Temperature at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</measure>
    <time_frame>12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment</time_frame>
    <description>Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Temperature at Each Time Point in Participants Randomized to Baloxavir or Placebo</measure>
    <time_frame>12, 24, 36, 48, 72, 96 and 120 hours after the initial dose of study treatment</time_frame>
    <description>Participant's self-measured axillary temperature using an electronic thermometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Temperature at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</measure>
    <time_frame>12, 24, 36, 48, 72, 96 and 120 hours after the initial dose of study treatment</time_frame>
    <description>Participant's self-measured axillary temperature using an electronic thermometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Alleviation of Individual Symptoms in Participants Randomized to Baloxavir or Placebo</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Alleviation of Individual Symptoms in Adults Randomized to Baloxavir or Oseltamivir</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return to Preinfluenza Health Status in Participants Randomized to Baloxavir or Placebo</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health [for someone your age and your health condition]), and their health status every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score.
Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Return to Preinfluenza Health Status in Adults Randomized to Baloxavir or Oseltamivir</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health [for someone your age and your health condition]), and their health status every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score.
Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Influenza-related Complications in Participants Randomized to Baloxavir or Placebo</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>The percentage of participants who experienced each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically confirmed pneumonia) as an adverse event after the initiation of the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Influenza-related Complications in Adults Randomized to Baloxavir or Oseltamivir</measure>
    <time_frame>Initiation of study treatment up to Day 14</time_frame>
    <description>The percentage of participants who experienced each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically confirmed pneumonia) as an adverse event after the initiation of the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs)</measure>
    <time_frame>From first dose of study drug to Day 22</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1436</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Adults: Baloxavir Marboxil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 20 to 64 years will receive two or four 20 mg baloxavir marboxil tablets orally on Day 1 and one oseltamivir placebo capsule orally twice a day (BID) on Days 1 to 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adults: Oseltamivir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants aged 20 to 64 years will receive 75 mg oseltamivir twice a day on Days 1 to 5 and two or four baloxavir marboxil placebo tablets on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adults: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants aged 20 to 64 years will receive two or four baloxavir marboxil placebo tablets on Day 1 and one oseltamivir placebo capsule orally twice a day on Days 1 to 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adolescents: Baloxavir Marboxil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 12 to 19 years will receive two or four baloxavir marboxil 20 mg tablets on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adolescents: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants aged 12 to 19 years will receive two or four baloxavir marboxil placebo tablets on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baloxavir Marboxil</intervention_name>
    <description>2 to4 X 20-mg tablets taken orally</description>
    <arm_group_label>Adolescents: Baloxavir Marboxil</arm_group_label>
    <arm_group_label>Adults: Baloxavir Marboxil</arm_group_label>
    <other_name>S-033188</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Baloxavir Marboxil</intervention_name>
    <description>2 to4 X 20-mg tablets taken orally</description>
    <arm_group_label>Adolescents: Placebo</arm_group_label>
    <arm_group_label>Adults: Oseltamivir</arm_group_label>
    <arm_group_label>Adults: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir</intervention_name>
    <description>75 mg capsules taken orally</description>
    <arm_group_label>Adults: Oseltamivir</arm_group_label>
    <other_name>Tamiflu®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Oseltamivir</intervention_name>
    <description>Placebo capsules matching oseltamivir 75 mg capsules</description>
    <arm_group_label>Adults: Baloxavir Marboxil</arm_group_label>
    <arm_group_label>Adults: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who are able to understand the study and comply with all study procedures,
             and willing to provide written informed consent/assent prior to the predose
             examinations appropriately. As for adolescent patients, informed consent/assent of
             voluntary participation should be obtained in accordance with local requirements

          2. Male or female patients aged ≥ 12 to ≤ 64 years at the time of signing the informed
             consent/assent form.

          3. Patients with a diagnosis of influenza virus infection confirmed by all of the
             following:

               1. Fever ≥ 38ºC (axillary) in the predose examinations or &gt; 4 hours after dosing of
                  antipyretics if they were taken

               2. At least one of the following general systemic symptoms associated with influenza
                  are present with a severity of moderate or greater

                    -  Headache

                    -  Feverishness or chills

                    -  Muscle or joint pain

                    -  Fatigue

               3. At least one of the following respiratory symptoms associated with influenza are
                  present with a severity of moderate or greater

                    -  Cough

                    -  Sore throat

                    -  Nasal congestion

          4. The time interval between the onset of symptoms and the predose examinations is 48
             hours or less. The onset of symptoms is defined as either:

               1. Time of the first increase in body temperature (an increase of at least 1ºC from
                  normal body temperature)

               2. Time when the patient experiences at least one general or respiratory symptom

          5. Women of childbearing potential who agree to use a highly effective method of
             contraception for 3 months after the first dose of study drug

        Exclusion Criteria:

          1. Patients with severe influenza virus infection requiring inpatient treatment.

          2. Patients aged ≥ 20 years with known allergy to oseltamivir (Tamiflu®).

          3. Patients with any of the following risk factors

               1. Women who are pregnant or within 2 weeks post-partum

               2. Residents of long-term care facilities (eg, welfare facilities for the elderly,
                  nursing homes)

               3. Chronic respiratory diseases including bronchial asthma

               4. Neurological and neurodevelopmental disorders including disorders of the brain,
                  spinal cord, peripheral nerve, and muscle (eg, cerebral palsy, epilepsy [seizure
                  disorders], stroke, intellectual disability, moderate to severe developmental
                  delay, muscular dystrophy, or spinal cord injury)

               5. Heart disease (such as congenital heart disease, congestive heart failure, or
                  coronary artery disease), excluding hypertension without any other heart-related
                  symptoms)

               6. American Indians and Alaskan natives

               7. Blood disorders (such as sickle cell disease)

               8. Endocrine disorders (including diabetes mellitus)

               9. Kidney disorders

              10. Liver disorders

              11. Metabolic disorders

              12. Compromised immune system (including patients receiving immunosuppressant
                  therapy, or those with cancer or human immunodeficiency virus [HIV] infection)

              13. Morbid obesity (body mass index [BMI] ≥ 40)

          4. Patients unable to swallow tablets or capsules.

          5. Patients who have previously received Baloxavir Marboxil.

          6. Patients weighing &lt; 40 kg

          7. Patients who have been exposed to an investigational drug within 30 days prior to the
             predose examinations.

          8. Women who are breastfeeding or have a positive pregnancy test in the predose
             examinations. The following female patients who have documentation of either a or b
             below do not need to undergo a pregnancy test in the predose examinations:

               1. Postmenopausal (defined as cessation of regular menstrual periods for 2 years or
                  more and confirmed by a follicle-stimulating hormone test) women

               2. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or
                  tubal ligation

          9. Patients with concurrent infections requiring systemic antimicrobial and/or antiviral
             therapy at the predose examinations.

         10. Patients who have received peramivir, laninamivir, oseltamivir, zanamivir,
             rimantadine, umifenovir, or amantadine within 30 days prior to the predose
             examinations.

         11. Patients who have received an investigational monoclonal antibody for a viral disease
             in the last year.

         12. Patients with severe underlying diseases.

         13. Patients with known creatinine clearance ≤ 60 mL/min.

         14. Patients who, in the opinion of the investigator, would be unlikely to comply with
             required study visits, self-assessments, and interventions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Support Help Line Shionogi Clinical Trials Administrator</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Thailand</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A; Baloxavir Marboxil Investigators Group. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018 Sep 6;379(10):913-923. doi: 10.1056/NEJMoa1716197.</citation>
    <PMID>30184455</PMID>
  </results_reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 27, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <results_first_submitted>November 20, 2018</results_first_submitted>
  <results_first_submitted_qc>November 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 14, 2018</results_first_posted>
  <disposition_first_submitted>March 1, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 1, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 5, 2018</disposition_first_posted>
  <last_update_submitted>April 24, 2019</last_update_submitted>
  <last_update_submitted_qc>April 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Flu</keyword>
  <keyword>Baloxavir Marboxil</keyword>
  <keyword>Oseltamivir</keyword>
  <keyword>Tamiflu®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
    <mesh_term>Baloxavir</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 31, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT02954354/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 6, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT02954354/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 297 sites, consisting of 141 sites in Japan, 149 sites in the United States, and 7 sites in Canada. Participants were enrolled from December 2016 to April 2017.</recruitment_details>
      <pre_assignment_details>Participants 20 to 64 years of age were randomly assigned in a 2:2:1 ratio to receive a single oral dose of baloxavir, 75 mg oseltamivir twice daily for 5 days, or matching placebos.
Participants 12 to 19 years of age were randomly assigned in a 2:1 ratio to receive a single dose of either baloxavir or placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Baloxavir</title>
          <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Oseltamivir</title>
          <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="612"/>
                <participants group_id="P2" count="310"/>
                <participants group_id="P3" count="514"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="610"/>
                <participants group_id="P2" count="309"/>
                <participants group_id="P3" count="513"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intention to Treat Infected Population</title>
              <participants_list>
                <participants group_id="P1" count="456"/>
                <participants group_id="P2" count="231"/>
                <participants group_id="P3" count="377"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="578"/>
                <participants group_id="P2" count="290"/>
                <participants group_id="P3" count="498"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to Meet Eligibility Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention-to-treat infection (ITTI) population consisting of participants who received study drug with a confirmed diagnosis of influenza. Confirmation of influenza was based on the results of reverse transcription polymerase chain reaction (RT-PCR) on Day 1.</population>
      <group_list>
        <group group_id="B1">
          <title>Baloxavir</title>
          <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Oseltamivir</title>
          <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="456"/>
            <count group_id="B2" value="231"/>
            <count group_id="B3" value="377"/>
            <count group_id="B4" value="1064"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Note that the baloxavir and placebo groups included participants from 12 to 64 years of age whereas the oseltamivir group only included participants from 20 to 64 years of age.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" spread="13.5"/>
                    <measurement group_id="B2" value="33.9" spread="13.7"/>
                    <measurement group_id="B3" value="36.0" spread="11.8"/>
                    <measurement group_id="B4" value="34.5" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>≥ 12 to ≤ 19 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 20 to ≤ 29 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="134"/>
                    <measurement group_id="B4" value="316"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 30 to ≤ 39 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="243"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 40 to ≤ 49 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="222"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 50 to ≤ 59 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 60 to ≤ 64 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="159"/>
                    <measurement group_id="B4" value="494"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="218"/>
                    <measurement group_id="B4" value="570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="424"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="352"/>
                    <measurement group_id="B4" value="996"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="349"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="305"/>
                    <measurement group_id="B4" value="832"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="185"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time From Symptom Onset to Initiation of the Trial Regimen</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>≥ 0 to ≤ 12 hours</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 12 to ≤ 24 hours</title>
                  <measurement_list>
                    <measurement group_id="B1" value="178"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="163"/>
                    <measurement group_id="B4" value="428"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 24 to ≤ 36 hours</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="300"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 36 to ≤ 48 hours</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Influenza Virus Type or Subtype on RT-PCR Assay at Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>A/H1N1pdm</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>A/H3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="393"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="332"/>
                    <measurement group_id="B4" value="921"/>
                  </measurement_list>
                </category>
                <category>
                  <title>B</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed infection</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Japan/Asia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="343"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="303"/>
                    <measurement group_id="B4" value="821"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rest of the world</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Composite Symptom Score</title>
          <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant, and ranges from 0 to 21.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>≤ 11</title>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="119"/>
                    <measurement group_id="B4" value="335"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 12</title>
                  <measurement_list>
                    <measurement group_id="B1" value="312"/>
                    <measurement group_id="B2" value="159"/>
                    <measurement group_id="B3" value="258"/>
                    <measurement group_id="B4" value="729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Alleviation of Symptoms in Participants Randomized to Baloxavir or Placebo</title>
        <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours.
Time to alleviation of symptoms was analyzed using the Kaplan-Meier (KM) method; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
        <time_frame>Initiation of study treatment up to Day 14</time_frame>
        <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo with available time to alleviation of symptoms data.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Alleviation of Symptoms in Participants Randomized to Baloxavir or Placebo</title>
          <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours.
Time to alleviation of symptoms was analyzed using the Kaplan-Meier (KM) method; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
          <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo with available time to alleviation of symptoms data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="455"/>
                <count group_id="O2" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7" lower_limit="49.5" upper_limit="58.5"/>
                    <measurement group_id="O2" value="80.2" lower_limit="72.6" upper_limit="87.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis of time to alleviation of symptoms was a comparison of baloxavir with placebo in all participants in the intention-to-treat infection population. Statistical tests were performed at the 0.05 significance level.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted p-value, two-sided significance level of 0.05</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>-26.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.8</ci_lower_limit>
            <ci_upper_limit>-17.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis using the stratified log rank test was performed as a sensitivity analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Log rank test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Alleviation of Symptoms in Adults Randomized to Baloxavir or Oseltamivir</title>
        <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours.
Time to alleviation of symptoms was analyzed using the Kaplan-Meier(KM) method; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
        <time_frame>Initiation of study treatment up to Day 14</time_frame>
        <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, and with available time to alleviation of symptoms data.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Alleviation of Symptoms in Adults Randomized to Baloxavir or Oseltamivir</title>
          <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours.
Time to alleviation of symptoms was analyzed using the Kaplan-Meier(KM) method; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
          <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, and with available time to alleviation of symptoms data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.5" lower_limit="48.0" upper_limit="58.5"/>
                    <measurement group_id="O2" value="53.8" lower_limit="50.2" upper_limit="56.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A secondary analysis of time to alleviation of symptoms, consisting of a comparison between the 20 to 64 years of age stratum of the baloxavir group and the oseltamivir group, was conducted if statistical significance was observed in the primary analysis in order to maintain the overall Type I error.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7560</p_value>
            <p_value_desc>Adjusted p-value, two-sided significance level of 0.05</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>6.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis using the stratified log rank test was performed as a sensitivity analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3761</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Log rank test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Positive Influenza Virus Titer at Each Time Point in Participants Randomized to Baloxavir or Placebo</title>
        <description>Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6 and 9.</description>
        <time_frame>Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
        <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo, with positive influenza virus titer on Day 1 and with available virus titer data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Positive Influenza Virus Titer at Each Time Point in Participants Randomized to Baloxavir or Placebo</title>
          <description>Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6 and 9.</description>
          <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo, with positive influenza virus titer on Day 1 and with available virus titer data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="414"/>
                    <count group_id="O2" value="201"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.6" lower_limit="42.7" upper_limit="52.5"/>
                    <measurement group_id="O2" value="96.0" lower_limit="92.3" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" lower_limit="17.8" upper_limit="26.0"/>
                    <measurement group_id="O2" value="70.5" lower_limit="63.5" upper_limit="76.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                    <count group_id="O2" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="10.3" upper_limit="24.8"/>
                    <measurement group_id="O2" value="56.1" lower_limit="42.4" upper_limit="69.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" lower_limit="10.4" upper_limit="17.3"/>
                    <measurement group_id="O2" value="29.7" lower_limit="23.3" upper_limit="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="3.6" upper_limit="15.6"/>
                    <measurement group_id="O2" value="12.5" lower_limit="4.7" upper_limit="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="408"/>
                    <count group_id="O2" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.5" upper_limit="5.1"/>
                    <measurement group_id="O2" value="4.6" lower_limit="2.1" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 5</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4767</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 9</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3353</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Positive Influenza Virus Titer at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</title>
        <description>Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6 and 9.</description>
        <time_frame>Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
        <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with positive influenza virus titer on Day 1 and with available virus titer data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Positive Influenza Virus Titer at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</title>
          <description>Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6 and 9.</description>
          <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with positive influenza virus titer on Day 1 and with available virus titer data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="359"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="340"/>
                    <count group_id="O2" value="348"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" lower_limit="41.9" upper_limit="52.8"/>
                    <measurement group_id="O2" value="91.1" lower_limit="87.6" upper_limit="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="335"/>
                    <count group_id="O2" value="344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="15.8" upper_limit="24.7"/>
                    <measurement group_id="O2" value="57.3" lower_limit="51.9" upper_limit="62.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" lower_limit="9.1" upper_limit="25.5"/>
                    <measurement group_id="O2" value="27.6" lower_limit="19.3" upper_limit="37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="333"/>
                    <count group_id="O2" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" lower_limit="9.5" upper_limit="17.0"/>
                    <measurement group_id="O2" value="20.8" lower_limit="16.6" upper_limit="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="1.6" upper_limit="13.8"/>
                    <measurement group_id="O2" value="9.0" lower_limit="3.7" upper_limit="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="336"/>
                    <count group_id="O2" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="1.4" upper_limit="5.4"/>
                    <measurement group_id="O2" value="3.2" lower_limit="1.6" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0852</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 5</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0063</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6187</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 9</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8637</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point in Participants Randomized to Baloxavir or Placebo</title>
        <description>Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) among those assessed measured by reverse transcription polymerase chain reaction (RT-PCR) on Days 2, 3, 4, 5, 6 and 9.</description>
        <time_frame>Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
        <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo, with positive influenza virus RNA determined by RT-PCR on Day 1 and with available data at each time point were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point in Participants Randomized to Baloxavir or Placebo</title>
          <description>Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) among those assessed measured by reverse transcription polymerase chain reaction (RT-PCR) on Days 2, 3, 4, 5, 6 and 9.</description>
          <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo, with positive influenza virus RNA determined by RT-PCR on Day 1 and with available data at each time point were included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="456"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="443"/>
                    <count group_id="O2" value="222"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3" lower_limit="95.3" upper_limit="98.6"/>
                    <measurement group_id="O2" value="97.7" lower_limit="94.8" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="436"/>
                    <count group_id="O2" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6" lower_limit="93.3" upper_limit="97.4"/>
                    <measurement group_id="O2" value="97.2" lower_limit="94.0" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.4" lower_limit="87.5" upper_limit="97.1"/>
                    <measurement group_id="O2" value="91.0" lower_limit="81.5" upper_limit="96.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="436"/>
                    <count group_id="O2" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.4" lower_limit="83.9" upper_limit="90.4"/>
                    <measurement group_id="O2" value="93.9" lower_limit="89.8" upper_limit="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.8" lower_limit="65.2" upper_limit="82.8"/>
                    <measurement group_id="O2" value="77.2" lower_limit="64.2" upper_limit="87.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="436"/>
                    <count group_id="O2" value="217"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" lower_limit="56.7" upper_limit="66.1"/>
                    <measurement group_id="O2" value="72.4" lower_limit="65.9" upper_limit="78.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6145</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2505</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4190</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 5</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0095</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7393</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 9</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0049</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</title>
        <description>Influenza virus RNA was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) among those assessed measured by reverse transcription polymerase chain reaction (RT-PCR) on Days 2, 3, 4, 5, 6 and 9.</description>
        <time_frame>Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
        <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with positive influenza virus RNA determined by RT-PCR on Day 1, and with available data at each time point were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</title>
          <description>Influenza virus RNA was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) among those assessed measured by reverse transcription polymerase chain reaction (RT-PCR) on Days 2, 3, 4, 5, 6 and 9.</description>
          <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with positive influenza virus RNA determined by RT-PCR on Day 1, and with available data at each time point were included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="364"/>
                    <count group_id="O2" value="362"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3" lower_limit="95.0" upper_limit="98.7"/>
                    <measurement group_id="O2" value="98.6" lower_limit="96.8" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="360"/>
                    <count group_id="O2" value="362"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.3" lower_limit="92.5" upper_limit="97.2"/>
                    <measurement group_id="O2" value="97.5" lower_limit="95.3" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.6" lower_limit="86.6" upper_limit="97.6"/>
                    <measurement group_id="O2" value="93.0" lower_limit="86.8" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="358"/>
                    <count group_id="O2" value="353"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.6" lower_limit="82.6" upper_limit="89.9"/>
                    <measurement group_id="O2" value="92.1" lower_limit="88.7" upper_limit="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" lower_limit="57.6" upper_limit="79.5"/>
                    <measurement group_id="O2" value="80.7" lower_limit="70.6" upper_limit="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="359"/>
                    <count group_id="O2" value="360"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.2" lower_limit="54.9" upper_limit="65.3"/>
                    <measurement group_id="O2" value="64.7" lower_limit="59.5" upper_limit="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2266</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1379</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5479</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 5</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0241</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0898</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 9</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2548</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Virus Titer at Each Time Point in Participants Randomized to Baloxavir or Placebo</title>
        <description>Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods.
If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).</description>
        <time_frame>Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
        <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo, with positive influenza virus titer on Day 1 and with available virus titer data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Virus Titer at Each Time Point in Participants Randomized to Baloxavir or Placebo</title>
          <description>Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods.
If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).</description>
          <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo, with positive influenza virus titer on Day 1 and with available virus titer data at each time point.</population>
          <units>log₁₀[TCID₅₀/mL]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="414"/>
                    <count group_id="O2" value="201"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.45" spread="2.03"/>
                    <measurement group_id="O2" value="-1.19" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="193"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.82" spread="1.99"/>
                    <measurement group_id="O2" value="-2.88" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="114"/>
                    <count group_id="O2" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.50" spread="2.02"/>
                    <measurement group_id="O2" value="-3.31" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.95" spread="1.93"/>
                    <measurement group_id="O2" value="-4.47" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.58" spread="1.99"/>
                    <measurement group_id="O2" value="-4.68" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="408"/>
                    <count group_id="O2" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.06" spread="1.87"/>
                    <measurement group_id="O2" value="-4.87" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0008</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 5</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0132</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9307</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 9</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1677</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Virus Titer at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</title>
        <description>Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods.
If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).</description>
        <time_frame>Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
        <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with positive influenza virus titer on Day 1 and with available virus titer data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Virus Titer at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</title>
          <description>Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods.
If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).</description>
          <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with positive influenza virus titer on Day 1 and with available virus titer data at each time point.</population>
          <units>log₁₀[TCID₅₀/mL]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="352"/>
                <count group_id="O2" value="359"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="340"/>
                    <count group_id="O2" value="348"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.39" spread="2.07"/>
                    <measurement group_id="O2" value="-2.53" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="335"/>
                    <count group_id="O2" value="344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.79" spread="2.03"/>
                    <measurement group_id="O2" value="-4.20" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.46" spread="2.03"/>
                    <measurement group_id="O2" value="-4.63" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="333"/>
                    <count group_id="O2" value="336"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.95" spread="1.94"/>
                    <measurement group_id="O2" value="-4.98" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.56" spread="1.99"/>
                    <measurement group_id="O2" value="-4.85" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="336"/>
                    <count group_id="O2" value="340"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.03" spread="1.89"/>
                    <measurement group_id="O2" value="-5.22" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8010</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 5</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9451</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2256</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 9</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3332</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Virus RNA (RT-PCR) at Each Time Point in Participants Randomized to Baloxavir or Placebo</title>
        <description>Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA is measured by reverse transcription polymerase chain reaction (RT-PCR).</description>
        <time_frame>Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
        <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo, with positive influenza virus titer on Day 1 and with available virus RNA data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Virus RNA (RT-PCR) at Each Time Point in Participants Randomized to Baloxavir or Placebo</title>
          <description>Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA is measured by reverse transcription polymerase chain reaction (RT-PCR).</description>
          <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo, with positive influenza virus titer on Day 1 and with available virus RNA data at each time point.</population>
          <units>log₁₀ virus particles/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="456"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="431"/>
                    <count group_id="O2" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.63" spread="1.03"/>
                    <measurement group_id="O2" value="-0.56" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="205"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.80" spread="1.20"/>
                    <measurement group_id="O2" value="-1.61" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="120"/>
                    <count group_id="O2" value="66"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.07" spread="1.59"/>
                    <measurement group_id="O2" value="-1.95" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                    <count group_id="O2" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.75" spread="1.47"/>
                    <measurement group_id="O2" value="-3.04" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.83" spread="1.64"/>
                    <measurement group_id="O2" value="-3.03" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                    <count group_id="O2" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.43" spread="1.42"/>
                    <measurement group_id="O2" value="-4.06" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 5</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0010</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 9</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Virus RNA (RT-PCR) at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</title>
        <description>Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA was measured by reverse transcription polymerase chain reaction (RT-PCR).</description>
        <time_frame>Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9</time_frame>
        <population>Participants in the intention-to-treat infection population ≥ 20 years of age and assigned to baloxavir or oseltamivir, with positive influenza virus titer on Day 1 and with available virus RNA data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Virus RNA (RT-PCR) at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</title>
          <description>Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA was measured by reverse transcription polymerase chain reaction (RT-PCR).</description>
          <population>Participants in the intention-to-treat infection population ≥ 20 years of age and assigned to baloxavir or oseltamivir, with positive influenza virus titer on Day 1 and with available virus RNA data at each time point.</population>
          <units>log₁₀ virus particles/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="355"/>
                    <count group_id="O2" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.61" spread="1.06"/>
                    <measurement group_id="O2" value="-1.10" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="350"/>
                    <count group_id="O2" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.79" spread="1.21"/>
                    <measurement group_id="O2" value="-2.44" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="112"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.94" spread="1.62"/>
                    <measurement group_id="O2" value="-2.97" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="348"/>
                    <count group_id="O2" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.76" spread="1.44"/>
                    <measurement group_id="O2" value="-3.62" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.81" spread="1.52"/>
                    <measurement group_id="O2" value="-3.88" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="351"/>
                    <count group_id="O2" value="349"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.43" spread="1.43"/>
                    <measurement group_id="O2" value="-4.52" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4148</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 5</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0338</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9619</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 9</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8491</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Participants Randomized to Baloxavir or Placebo</title>
        <description>This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.</description>
        <time_frame>Day 1 to Day 9</time_frame>
        <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo, with a positive virus titer on Day 1 and available sample on Day 9.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Participants Randomized to Baloxavir or Placebo</title>
          <description>This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.</description>
          <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo, with a positive virus titer on Day 1 and available sample on Day 9.</population>
          <units>log₁₀[TCID₅₀/mL]*hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-836.2" spread="348.9"/>
                    <measurement group_id="O2" value="-641.8" spread="377.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Adults Randomized to Baloxavir or Oseltamivir</title>
        <description>This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.</description>
        <time_frame>Day 1 to Day 9</time_frame>
        <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with a positive virus titer on Day 1 and available sample on Day 9.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer in Adults Randomized to Baloxavir or Oseltamivir</title>
          <description>This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.</description>
          <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with a positive virus titer on Day 1 and available sample on Day 9.</population>
          <units>log₁₀[TCID₅₀/mL]*hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="340"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-829.6" spread="350.3"/>
                    <measurement group_id="O2" value="-790.2" spread="328.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0313</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) Adjusted by Baseline of Influenza Virus RNA in Participants Randomized to Baloxavir or Placebo</title>
        <description>This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.</description>
        <time_frame>Day 1 to Day 9</time_frame>
        <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo with a positive virus RNA determined by RT-PCR at baseline and available sample on Day 9.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) Adjusted by Baseline of Influenza Virus RNA in Participants Randomized to Baloxavir or Placebo</title>
          <description>This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.</description>
          <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo with a positive virus RNA determined by RT-PCR at baseline and available sample on Day 9.</population>
          <units>log₁₀ virus particles/mL*hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="426"/>
                <count group_id="O2" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-582.0" spread="230.9"/>
                    <measurement group_id="O2" value="-456.8" spread="269.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) Adjusted by Baseline of Influenza Virus RNA in Adults Randomized to Baloxavir or Oseltamivir</title>
        <description>This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.</description>
        <time_frame>Day 1 to Day 9</time_frame>
        <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with a positive virus RNA determined by RT-PCR at baseline and available sample on Day 9.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) Adjusted by Baseline of Influenza Virus RNA in Adults Randomized to Baloxavir or Oseltamivir</title>
          <description>This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.</description>
          <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with a positive virus RNA determined by RT-PCR at baseline and available sample on Day 9.</population>
          <units>log₁₀ virus particles/mL*hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
                <count group_id="O2" value="349"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-581.0" spread="231.2"/>
                    <measurement group_id="O2" value="-569.7" spread="228.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2424</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>van Elteren test</method>
            <method_desc>Van Elteren test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cessation of Viral Shedding Determined by Virus Titer in Participants Randomized to Baloxavir or Placebo</title>
        <description>Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀[TCID₅₀/mL]). The median and 95% confidence interval (CI) for time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.</description>
        <time_frame>Day 1 to Day 9</time_frame>
        <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo with a positive virus titer on Day 1 whose time to cessation of viral shedding by virus titer was not missing were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cessation of Viral Shedding Determined by Virus Titer in Participants Randomized to Baloxavir or Placebo</title>
          <description>Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀[TCID₅₀/mL]). The median and 95% confidence interval (CI) for time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.</description>
          <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo with a positive virus titer on Day 1 whose time to cessation of viral shedding by virus titer was not missing were included in this analysis.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="426"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" lower_limit="24.0" upper_limit="48.0"/>
                    <measurement group_id="O2" value="96.0" lower_limit="NA" upper_limit="NA">Could not be estimated because lower limit of 95% CI of KM survival function just before the median survival time was higher than 50% and an upper limit of 95% CI of KM survival function just after the median survival time was lower than 50%.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>-72.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-72.0</ci_lower_limit>
            <ci_upper_limit>-48.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cessation of Viral Shedding Determined by Virus Titer in Adults Randomized to Baloxavir or Oseltamivir</title>
        <description>Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀[TCID₅₀/mL]). The time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.</description>
        <time_frame>Day 1 to Day 9</time_frame>
        <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with a positive virus titer on Day 1 whose time to cessation of viral shedding by virus titer was not missing..</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cessation of Viral Shedding Determined by Virus Titer in Adults Randomized to Baloxavir or Oseltamivir</title>
          <description>Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀[TCID₅₀/mL]). The time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.</description>
          <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with a positive virus titer on Day 1 whose time to cessation of viral shedding by virus titer was not missing..</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="351"/>
                <count group_id="O2" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" lower_limit="24.0" upper_limit="48.0"/>
                    <measurement group_id="O2" value="72.0" lower_limit="72.0" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>-48.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-72.0</ci_lower_limit>
            <ci_upper_limit>-24.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cessation of Viral Shedding Determined by Virus RNA in Participants Randomized to Baloxavir or Placebo</title>
        <description>Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR.
Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.</description>
        <time_frame>Day 1 to Day 9</time_frame>
        <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo, with positive influenza virus RNA determined by RT-PCR on Day 1 whose time to cessation of viral shedding by RTPCR was not missing were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cessation of Viral Shedding Determined by Virus RNA in Participants Randomized to Baloxavir or Placebo</title>
          <description>Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR.
Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.</description>
          <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo, with positive influenza virus RNA determined by RT-PCR on Day 1 whose time to cessation of viral shedding by RTPCR was not missing were included in this analysis.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="455"/>
                <count group_id="O2" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216.0" lower_limit="216.0" upper_limit="240.0"/>
                    <measurement group_id="O2" value="240.0" lower_limit="240.0" upper_limit="336.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0020</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>-24.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-120.0</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Cessation of Viral Shedding Determined by Virus RNA in Adults Randomized to Baloxavir or Oseltamivir</title>
        <description>Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR.
Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.</description>
        <time_frame>Day 1 to Day 9</time_frame>
        <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with positive influenza virus RNA determined by RT-PCR on Day 1 whose time to cessation of viral shedding by RTPCR was not missing were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cessation of Viral Shedding Determined by Virus RNA in Adults Randomized to Baloxavir or Oseltamivir</title>
          <description>Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR.
Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.</description>
          <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with positive influenza virus RNA determined by RT-PCR on Day 1 whose time to cessation of viral shedding by RTPCR was not missing were included in this analysis.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216.0" lower_limit="192.0" upper_limit="240.0"/>
                    <measurement group_id="O2" value="240.0" lower_limit="216.0" upper_limit="240.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0102</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>-24.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.0</ci_lower_limit>
            <ci_upper_limit>24.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Whose Symptoms Were Alleviated at Each Time Point in Participants Randomized to Baloxavir or Placebo</title>
        <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Alleviation of symptoms was defined as all seven influenza-related symptoms assessed by the participant as absent (0) or mild (1) .</description>
        <time_frame>12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment</time_frame>
        <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo with available alleviation of symptoms data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Whose Symptoms Were Alleviated at Each Time Point in Participants Randomized to Baloxavir or Placebo</title>
          <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Alleviation of symptoms was defined as all seven influenza-related symptoms assessed by the participant as absent (0) or mild (1) .</description>
          <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo with available alleviation of symptoms data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="456"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="373"/>
                    <count group_id="O2" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" lower_limit="6.9" upper_limit="13.1"/>
                    <measurement group_id="O2" value="8.1" lower_limit="4.7" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="445"/>
                    <count group_id="O2" value="218"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" lower_limit="19.3" upper_limit="27.3"/>
                    <measurement group_id="O2" value="12.8" lower_limit="8.7" upper_limit="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="361"/>
                    <count group_id="O2" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4" lower_limit="37.2" upper_limit="47.7"/>
                    <measurement group_id="O2" value="23.1" lower_limit="17.4" upper_limit="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="444"/>
                    <count group_id="O2" value="220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.7" lower_limit="45.9" upper_limit="55.4"/>
                    <measurement group_id="O2" value="26.4" lower_limit="20.7" upper_limit="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="431"/>
                    <count group_id="O2" value="216"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9" lower_limit="64.3" upper_limit="73.3"/>
                    <measurement group_id="O2" value="49.5" lower_limit="42.7" upper_limit="56.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="429"/>
                    <count group_id="O2" value="216"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6" lower_limit="74.4" upper_limit="82.3"/>
                    <measurement group_id="O2" value="69.9" lower_limit="63.3" upper_limit="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="415"/>
                    <count group_id="O2" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.5" lower_limit="81.8" upper_limit="88.8"/>
                    <measurement group_id="O2" value="81.6" lower_limit="75.7" upper_limit="86.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>144 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="404"/>
                    <count group_id="O2" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.1" lower_limit="85.7" upper_limit="92.0"/>
                    <measurement group_id="O2" value="85.4" lower_limit="79.7" upper_limit="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="403"/>
                    <count group_id="O2" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.6" lower_limit="88.4" upper_limit="94.1"/>
                    <measurement group_id="O2" value="88.3" lower_limit="83.0" upper_limit="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>192 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="87.7" upper_limit="93.5"/>
                    <measurement group_id="O2" value="91.4" lower_limit="86.5" upper_limit="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>216 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="224"/>
                    <count group_id="O2" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.1" lower_limit="86.5" upper_limit="94.5"/>
                    <measurement group_id="O2" value="91.9" lower_limit="85.2" upper_limit="96.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5973</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0010</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>36 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>72 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>96 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0115</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>120 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1298</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>144 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1170</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>168 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0757</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>192 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9453</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>216 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8657</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Whose Symptoms Were Alleviated at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</title>
        <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Alleviation of symptoms was defined as all seven influenza-related symptoms assessed by the participant as absent (0) or mild (1) .</description>
        <time_frame>12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment</time_frame>
        <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with available alleviation of symptoms data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Whose Symptoms Were Alleviated at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</title>
          <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Alleviation of symptoms was defined as all seven influenza-related symptoms assessed by the participant as absent (0) or mild (1) .</description>
          <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with available alleviation of symptoms data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="310"/>
                    <count group_id="O2" value="309"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="5.8" upper_limit="12.4"/>
                    <measurement group_id="O2" value="4.9" lower_limit="2.7" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="366"/>
                    <count group_id="O2" value="365"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" lower_limit="17.2" upper_limit="25.9"/>
                    <measurement group_id="O2" value="22.7" lower_limit="18.5" upper_limit="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="299"/>
                    <count group_id="O2" value="297"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1" lower_limit="35.5" upper_limit="46.9"/>
                    <measurement group_id="O2" value="38.7" lower_limit="33.1" upper_limit="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="365"/>
                    <count group_id="O2" value="360"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0" lower_limit="45.7" upper_limit="56.2"/>
                    <measurement group_id="O2" value="54.4" lower_limit="49.1" upper_limit="59.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="351"/>
                    <count group_id="O2" value="359"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7" lower_limit="65.6" upper_limit="75.4"/>
                    <measurement group_id="O2" value="73.0" lower_limit="68.1" upper_limit="77.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="351"/>
                    <count group_id="O2" value="359"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.8" lower_limit="75.2" upper_limit="83.9"/>
                    <measurement group_id="O2" value="80.5" lower_limit="76.0" upper_limit="84.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="339"/>
                    <count group_id="O2" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.1" lower_limit="82.0" upper_limit="89.6"/>
                    <measurement group_id="O2" value="87.0" lower_limit="82.9" upper_limit="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>144 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="334"/>
                    <count group_id="O2" value="334"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.2" lower_limit="85.4" upper_limit="92.3"/>
                    <measurement group_id="O2" value="91.3" lower_limit="87.8" upper_limit="94.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="336"/>
                    <count group_id="O2" value="334"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4" lower_limit="87.8" upper_limit="94.1"/>
                    <measurement group_id="O2" value="94.3" lower_limit="91.3" upper_limit="96.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>192 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="338"/>
                    <count group_id="O2" value="331"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.8" lower_limit="87.2" upper_limit="93.7"/>
                    <measurement group_id="O2" value="95.5" lower_limit="92.6" upper_limit="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>216 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="85.8" upper_limit="94.6"/>
                    <measurement group_id="O2" value="96.3" lower_limit="92.5" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0458</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7565</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>36 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3297</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4442</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>72 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6029</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>96 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9881</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>120 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9257</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>144 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5317</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>168 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2144</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>192 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0413</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>216 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0409</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Alleviation of the Four Systemic Symptoms in Participants Randomized to Baloxavir or Placebo</title>
        <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of the 4 systemic symptoms was defined as the time between the initiation of the study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.
Time to alleviation of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
        <time_frame>Initiation of study treatment up to Day 14</time_frame>
        <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo with available time to alleviation of the 4 systemic symptoms data.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Alleviation of the Four Systemic Symptoms in Participants Randomized to Baloxavir or Placebo</title>
          <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of the 4 systemic symptoms was defined as the time between the initiation of the study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.
Time to alleviation of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
          <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo with available time to alleviation of the 4 systemic symptoms data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="455"/>
                <count group_id="O2" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8" lower_limit="31.0" upper_limit="38.3"/>
                    <measurement group_id="O2" value="53.5" lower_limit="45.9" upper_limit="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>-19.8</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Alleviation of the Four Systemic Symptoms in Adults Randomized to Baloxavir or Oseltamivir</title>
        <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of the 4 systemic symptoms was defined as the time between the initiation of the study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.
Time to alleviation of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
        <time_frame>Initiation of study treatment up to Day 14</time_frame>
        <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with available time to alleviation of the 4 systemic symptoms data.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Alleviation of the Four Systemic Symptoms in Adults Randomized to Baloxavir or Oseltamivir</title>
          <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of the 4 systemic symptoms was defined as the time between the initiation of the study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.
Time to alleviation of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
          <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with available time to alleviation of the 4 systemic symptoms data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7" lower_limit="32.0" upper_limit="40.1"/>
                    <measurement group_id="O2" value="37.4" lower_limit="31.5" upper_limit="42.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4194</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>-0.7</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Alleviation of the Three Respiratory Symptoms in Participants Randomized to Baloxavir or Placebo</title>
        <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat and nasal congestion) were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours.
Time to alleviation of the 3 respiratory symptoms was analyzed using the KM method; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
        <time_frame>Initiation of study treatment up to Day 14</time_frame>
        <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo with available time to alleviation of the 3 respiratory symptoms data.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Alleviation of the Three Respiratory Symptoms in Participants Randomized to Baloxavir or Placebo</title>
          <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat and nasal congestion) were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours.
Time to alleviation of the 3 respiratory symptoms was analyzed using the KM method; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
          <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo with available time to alleviation of the 3 respiratory symptoms data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="455"/>
                <count group_id="O2" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0" lower_limit="43.4" upper_limit="50.6"/>
                    <measurement group_id="O2" value="69.1" lower_limit="63.9" upper_limit="78.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>-23.1</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Alleviation of the Three Respiratory Symptoms in Adults Randomized to Baloxavir or Oseltamivir</title>
        <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat and nasal congestion) were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours.
Time to alleviation of the 3 respiratory symptoms was analyzed using the KM method; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
        <time_frame>Initiation of study treatment up to Day 14</time_frame>
        <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with available time to alleviation of the 3 respiratory symptoms data.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Alleviation of the Three Respiratory Symptoms in Adults Randomized to Baloxavir or Oseltamivir</title>
          <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat and nasal congestion) were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours.
Time to alleviation of the 3 respiratory symptoms was analyzed using the KM method; participants who did not experience alleviation of symptoms were censored at the last observation time point.</description>
          <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with available time to alleviation of the 3 respiratory symptoms data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0" lower_limit="42.7" upper_limit="52.0"/>
                    <measurement group_id="O2" value="44.6" lower_limit="40.6" upper_limit="49.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4856</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>1.3</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Composite Symptom Score at Each Time Point in Participants Randomized to Baloxavir or Placebo</title>
        <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant, and ranges from 0 to 21.</description>
        <time_frame>Day 1 pretreatment (Baseline) and 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment.</time_frame>
        <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo with available composite symptom scores at Baseline and each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Composite Symptom Score at Each Time Point in Participants Randomized to Baloxavir or Placebo</title>
          <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant, and ranges from 0 to 21.</description>
          <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo with available composite symptom scores at Baseline and each time point.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="456"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="373"/>
                    <count group_id="O2" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="0.2"/>
                    <measurement group_id="O2" value="-2.5" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="445"/>
                    <count group_id="O2" value="218"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="0.2"/>
                    <measurement group_id="O2" value="-3.6" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="361"/>
                    <count group_id="O2" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="0.2"/>
                    <measurement group_id="O2" value="-4.9" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="444"/>
                    <count group_id="O2" value="220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="0.2"/>
                    <measurement group_id="O2" value="-6.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="431"/>
                    <count group_id="O2" value="216"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" spread="0.2"/>
                    <measurement group_id="O2" value="-8.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="429"/>
                    <count group_id="O2" value="216"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.5" spread="0.2"/>
                    <measurement group_id="O2" value="-9.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="415"/>
                    <count group_id="O2" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.9" spread="0.2"/>
                    <measurement group_id="O2" value="-10.6" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>144 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="404"/>
                    <count group_id="O2" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.6" spread="0.1"/>
                    <measurement group_id="O2" value="-11.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="403"/>
                    <count group_id="O2" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.9" spread="0.1"/>
                    <measurement group_id="O2" value="-11.8" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>192 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.0" spread="0.1"/>
                    <measurement group_id="O2" value="-12.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>216 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="224"/>
                    <count group_id="O2" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.4" spread="0.2"/>
                    <measurement group_id="O2" value="-12.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7173</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0009</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>36 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>-1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>-1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>72 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>96 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>-0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>120 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1979</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>144 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1079</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>168 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5805</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>192 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8057</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>216 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9525</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Composite Symptom Score at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</title>
        <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant, and ranges from 0 to 21.</description>
        <time_frame>Day 1 pretreatment (Baseline) and 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment.</time_frame>
        <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with available composite symptom scores at Baseline and each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Composite Symptom Score at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</title>
          <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
The composite symptom score is the total score of the 7 influenza symptoms as assessed by the participant, and ranges from 0 to 21.</description>
          <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with available composite symptom scores at Baseline and each time point.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="310"/>
                    <count group_id="O2" value="309"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="0.2"/>
                    <measurement group_id="O2" value="-2.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="366"/>
                    <count group_id="O2" value="365"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="0.2"/>
                    <measurement group_id="O2" value="-4.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="299"/>
                    <count group_id="O2" value="297"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="0.2"/>
                    <measurement group_id="O2" value="-6.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="365"/>
                    <count group_id="O2" value="360"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="0.2"/>
                    <measurement group_id="O2" value="-7.8" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="351"/>
                    <count group_id="O2" value="359"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" spread="0.2"/>
                    <measurement group_id="O2" value="-9.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="351"/>
                    <count group_id="O2" value="359"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.5" spread="0.2"/>
                    <measurement group_id="O2" value="-10.6" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="339"/>
                    <count group_id="O2" value="345"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.0" spread="0.2"/>
                    <measurement group_id="O2" value="-11.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>144 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="334"/>
                    <count group_id="O2" value="334"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="0.2"/>
                    <measurement group_id="O2" value="-11.8" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="336"/>
                    <count group_id="O2" value="334"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.9" spread="0.2"/>
                    <measurement group_id="O2" value="-12.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>192 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="338"/>
                    <count group_id="O2" value="331"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.0" spread="0.1"/>
                    <measurement group_id="O2" value="-12.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>216 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.4" spread="0.2"/>
                    <measurement group_id="O2" value="-12.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4091</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3073</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>36 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3465</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4285</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>72 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6703</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>96 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7187</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>120 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1350</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>144 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7046</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>168 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2765</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>192 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0274</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>216 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with baseline composite symptom score baseline (≤ 11 or ≥ 12)and region (Japan/Asia, Rest of the world) as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Fever in Participants Randomized to Baloxavir or Placebo</title>
        <description>Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours.
Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.</description>
        <time_frame>Initiation of study treatment up to Day 14</time_frame>
        <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo whose body temperature at baseline was more than 37°C and time to resolution of fever was not missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Fever in Participants Randomized to Baloxavir or Placebo</title>
          <description>Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours.
Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.</description>
          <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo whose body temperature at baseline was more than 37°C and time to resolution of fever was not missing.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" lower_limit="22.6" upper_limit="26.6"/>
                    <measurement group_id="O2" value="42.0" lower_limit="37.4" upper_limit="44.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>-17.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.1</ci_lower_limit>
            <ci_upper_limit>-11.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Resolution of Fever in Adults Randomized to Baloxavir or Oseltamivir</title>
        <description>Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours.
Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.</description>
        <time_frame>Initiation of study treatment up to Day 14</time_frame>
        <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, whose body temperature at baseline was more than 37°C and time to resolution of fever was not missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Fever in Adults Randomized to Baloxavir or Oseltamivir</title>
          <description>Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for a duration of at least 12 hours.
Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.</description>
          <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, whose body temperature at baseline was more than 37°C and time to resolution of fever was not missing.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="374"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" lower_limit="22.2" upper_limit="26.5"/>
                    <measurement group_id="O2" value="24.0" lower_limit="22.1" upper_limit="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9225</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Normal Temperature at Each Time Point in Participants Randomized to Baloxavir or Placebo</title>
        <description>Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment.</description>
        <time_frame>12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment</time_frame>
        <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo whose body temperature at baseline was more than 37°C with available body temperature data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Normal Temperature at Each Time Point in Participants Randomized to Baloxavir or Placebo</title>
          <description>Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment.</description>
          <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo whose body temperature at baseline was more than 37°C with available body temperature data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="449"/>
                <count group_id="O2" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="431"/>
                    <count group_id="O2" value="217"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" lower_limit="22.3" upper_limit="30.9"/>
                    <measurement group_id="O2" value="25.3" lower_limit="19.7" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="442"/>
                    <count group_id="O2" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3" lower_limit="59.6" upper_limit="68.7"/>
                    <measurement group_id="O2" value="48.4" lower_limit="41.8" upper_limit="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="428"/>
                    <count group_id="O2" value="218"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8" lower_limit="76.8" upper_limit="84.5"/>
                    <measurement group_id="O2" value="58.3" lower_limit="51.4" upper_limit="64.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="439"/>
                    <count group_id="O2" value="220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3" lower_limit="86.0" upper_limit="92.0"/>
                    <measurement group_id="O2" value="67.3" lower_limit="60.6" upper_limit="73.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="413"/>
                    <count group_id="O2" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7" lower_limit="90.9" upper_limit="95.8"/>
                    <measurement group_id="O2" value="83.8" lower_limit="77.8" upper_limit="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="400"/>
                    <count group_id="O2" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8" lower_limit="89.8" upper_limit="95.1"/>
                    <measurement group_id="O2" value="93.9" lower_limit="89.6" upper_limit="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="392"/>
                    <count group_id="O2" value="194"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9" lower_limit="89.8" upper_limit="95.2"/>
                    <measurement group_id="O2" value="92.8" lower_limit="88.2" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>144 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="379"/>
                    <count group_id="O2" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.4" lower_limit="90.4" upper_limit="95.7"/>
                    <measurement group_id="O2" value="93.6" lower_limit="89.1" upper_limit="96.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="375"/>
                    <count group_id="O2" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3" lower_limit="90.3" upper_limit="95.6"/>
                    <measurement group_id="O2" value="93.6" lower_limit="89.1" upper_limit="96.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>192 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1" lower_limit="91.2" upper_limit="96.3"/>
                    <measurement group_id="O2" value="93.7" lower_limit="89.3" upper_limit="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>216 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="372"/>
                    <count group_id="O2" value="191"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" lower_limit="89.3" upper_limit="94.9"/>
                    <measurement group_id="O2" value="92.7" lower_limit="88.0" upper_limit="95.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7866</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>36 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>72 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>96 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7044</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>120 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8512</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>144 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8783</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>168 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8291</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>192 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8644</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>216 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9312</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Normal Temperature at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</title>
        <description>Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment.</description>
        <time_frame>12, 24, 36, 48, 72, 96, 120, 144, 168, 192 and 216 hours after the initial dose of study treatment</time_frame>
        <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, whose body temperature at baseline was more than 37°C with available body temperature data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Normal Temperature at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</title>
          <description>Defined as the percentage of patients whose axillary temperature dropped to less than 37ºC after the initiation of study treatment.</description>
          <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, whose body temperature at baseline was more than 37°C with available body temperature data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="370"/>
                <count group_id="O2" value="374"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="360"/>
                    <count group_id="O2" value="353"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" lower_limit="20.6" upper_limit="29.8"/>
                    <measurement group_id="O2" value="28.3" lower_limit="23.7" upper_limit="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="364"/>
                    <count group_id="O2" value="367"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3" lower_limit="59.1" upper_limit="69.2"/>
                    <measurement group_id="O2" value="66.8" lower_limit="61.7" upper_limit="71.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="354"/>
                    <count group_id="O2" value="359"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.9" lower_limit="77.5" upper_limit="85.8"/>
                    <measurement group_id="O2" value="79.1" lower_limit="74.5" upper_limit="83.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="363"/>
                    <count group_id="O2" value="366"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.1" lower_limit="86.5" upper_limit="93.0"/>
                    <measurement group_id="O2" value="89.9" lower_limit="86.3" upper_limit="92.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="339"/>
                    <count group_id="O2" value="344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8" lower_limit="90.7" upper_limit="96.1"/>
                    <measurement group_id="O2" value="89.5" lower_limit="85.8" upper_limit="92.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="329"/>
                    <count group_id="O2" value="334"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.9" lower_limit="90.8" upper_limit="96.2"/>
                    <measurement group_id="O2" value="94.9" lower_limit="92.0" upper_limit="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="324"/>
                    <count group_id="O2" value="335"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8" lower_limit="90.6" upper_limit="96.2"/>
                    <measurement group_id="O2" value="95.8" lower_limit="93.1" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>144 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="320"/>
                    <count group_id="O2" value="328"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8" lower_limit="89.4" upper_limit="95.4"/>
                    <measurement group_id="O2" value="94.5" lower_limit="91.5" upper_limit="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>168 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="314"/>
                    <count group_id="O2" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.6" lower_limit="90.3" upper_limit="96.1"/>
                    <measurement group_id="O2" value="95.9" lower_limit="93.0" upper_limit="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>192 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="313"/>
                    <count group_id="O2" value="308"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.6" lower_limit="91.4" upper_limit="96.8"/>
                    <measurement group_id="O2" value="95.8" lower_limit="92.9" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>216 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="305"/>
                    <count group_id="O2" value="309"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8" lower_limit="89.3" upper_limit="95.4"/>
                    <measurement group_id="O2" value="94.5" lower_limit="91.3" upper_limit="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2953</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5414</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>36 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2079</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7771</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>72 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0215</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>96 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8033</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>120 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4157</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>144 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5908</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>168 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2975</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>192 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8644</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>216 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5573</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.m</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>Mantel-Haenszel test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Temperature at Each Time Point in Participants Randomized to Baloxavir or Placebo</title>
        <description>Participant's self-measured axillary temperature using an electronic thermometer.</description>
        <time_frame>12, 24, 36, 48, 72, 96 and 120 hours after the initial dose of study treatment</time_frame>
        <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo with available temperature data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Temperature at Each Time Point in Participants Randomized to Baloxavir or Placebo</title>
          <description>Participant's self-measured axillary temperature using an electronic thermometer.</description>
          <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo with available temperature data at each time point.</population>
          <units>°C</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="456"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="435"/>
                    <count group_id="O2" value="218"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.40" spread="0.05"/>
                    <measurement group_id="O2" value="37.49" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="447"/>
                    <count group_id="O2" value="226"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.73" spread="0.04"/>
                    <measurement group_id="O2" value="37.07" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="432"/>
                    <count group_id="O2" value="219"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.49" spread="0.04"/>
                    <measurement group_id="O2" value="36.90" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="446"/>
                    <count group_id="O2" value="221"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.32" spread="0.03"/>
                    <measurement group_id="O2" value="36.69" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="418"/>
                    <count group_id="O2" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.26" spread="0.03"/>
                    <measurement group_id="O2" value="36.48" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="405"/>
                    <count group_id="O2" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.27" spread="0.03"/>
                    <measurement group_id="O2" value="36.31" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="396"/>
                    <count group_id="O2" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.28" spread="0.03"/>
                    <measurement group_id="O2" value="36.25" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2557</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>36 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.52</ci_lower_limit>
            <ci_upper_limit>-0.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>72 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>-0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>96 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4484</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Dfference</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5963</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Temperature at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</title>
        <description>Participant's self-measured axillary temperature using an electronic thermometer.</description>
        <time_frame>12, 24, 36, 48, 72, 96 and 120 hours after the initial dose of study treatment</time_frame>
        <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with available temperature data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Temperature at Each Time Point in Adults Randomized to Baloxavir or Oseltamivir</title>
          <description>Participant's self-measured axillary temperature using an electronic thermometer.</description>
          <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, with available temperature data at each time point.</population>
          <units>°C</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="363"/>
                    <count group_id="O2" value="355"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.47" spread="0.05"/>
                    <measurement group_id="O2" value="37.35" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="368"/>
                    <count group_id="O2" value="369"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.78" spread="0.04"/>
                    <measurement group_id="O2" value="36.73" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="358"/>
                    <count group_id="O2" value="362"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.55" spread="0.04"/>
                    <measurement group_id="O2" value="36.54" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="369"/>
                    <count group_id="O2" value="369"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.34" spread="0.03"/>
                    <measurement group_id="O2" value="36.36" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="344"/>
                    <count group_id="O2" value="346"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.30" spread="0.03"/>
                    <measurement group_id="O2" value="36.31" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>96 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="334"/>
                    <count group_id="O2" value="337"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.26" spread="0.03"/>
                    <measurement group_id="O2" value="36.23" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="328"/>
                    <count group_id="O2" value="337"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.27" spread="0.03"/>
                    <measurement group_id="O2" value="36.21" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>12 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0937</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3343</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>36 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9258</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>48 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6574</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>72 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8520</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>96 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4532</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>120 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1570</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with baseline composite symptom score and region (Japan/Asia, Rest of the world) and body temperature at baseline as covariates.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Alleviation of Individual Symptoms in Participants Randomized to Baloxavir or Placebo</title>
        <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.</description>
        <time_frame>Initiation of study treatment up to Day 14</time_frame>
        <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo whose symptom score at baseline was moderate (2) or severe (3) with available time to alleviation of symptoms data.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Alleviation of Individual Symptoms in Participants Randomized to Baloxavir or Placebo</title>
          <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.</description>
          <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo whose symptom score at baseline was moderate (2) or severe (3) with available time to alleviation of symptoms data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="455"/>
                <count group_id="O2" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cough</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="308"/>
                    <count group_id="O2" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" lower_limit="30.3" upper_limit="43.5"/>
                    <measurement group_id="O2" value="61.4" lower_limit="44.8" upper_limit="69.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Throat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" lower_limit="27.3" upper_limit="39.2"/>
                    <measurement group_id="O2" value="40.5" lower_limit="31.8" upper_limit="48.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="296"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" lower_limit="22.9" upper_limit="29.8"/>
                    <measurement group_id="O2" value="37.9" lower_limit="25.8" upper_limit="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="277"/>
                    <count group_id="O2" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" lower_limit="29.9" upper_limit="38.7"/>
                    <measurement group_id="O2" value="52.5" lower_limit="41.5" upper_limit="62.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feverishness or chills</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="408"/>
                    <count group_id="O2" value="214"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" lower_limit="20.0" upper_limit="21.9"/>
                    <measurement group_id="O2" value="25.8" lower_limit="21.7" upper_limit="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle or joint pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="353"/>
                    <count group_id="O2" value="169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" lower_limit="21.4" upper_limit="26.3"/>
                    <measurement group_id="O2" value="31.3" lower_limit="25.5" upper_limit="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="361"/>
                    <count group_id="O2" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3" lower_limit="22.0" upper_limit="29.2"/>
                    <measurement group_id="O2" value="40.5" lower_limit="31.2" upper_limit="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cough</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>-23.1</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sore throat</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0298</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>-9.0</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Headache</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0297</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>-11.8</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Nasal Congestion</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0027</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>-20.7</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Feverishness or chills</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world)</method_desc>
            <param_type>Difference</param_type>
            <param_value>-4.9</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Muscle or joint pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0094</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>-8.1</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fatigue</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0007</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>-15.3</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Alleviation of Individual Symptoms in Adults Randomized to Baloxavir or Oseltamivir</title>
        <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.</description>
        <time_frame>Initiation of study treatment up to Day 14</time_frame>
        <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, whose symptom score at baseline was moderate (2) or severe (3) with available time to alleviation of symptoms data.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Alleviation of Individual Symptoms in Adults Randomized to Baloxavir or Oseltamivir</title>
          <description>Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms).
Time to alleviation of each symptom was defined as the time from the start of treatment to the start of the time period when the individual symptom was assessed by the participant as 0 (None) or 1 (Mild) for a duration of at least 21.5 hours.</description>
          <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, whose symptom score at baseline was moderate (2) or severe (3) with available time to alleviation of symptoms data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cough</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="250"/>
                    <count group_id="O2" value="262"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2" lower_limit="30.3" upper_limit="43.4"/>
                    <measurement group_id="O2" value="31.4" lower_limit="28.6" upper_limit="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore Throat</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1" lower_limit="27.6" upper_limit="39.8"/>
                    <measurement group_id="O2" value="30.4" lower_limit="25.0" upper_limit="43.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="239"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" lower_limit="24.5" upper_limit="30.8"/>
                    <measurement group_id="O2" value="25.6" lower_limit="21.9" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal Congestion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="217"/>
                    <count group_id="O2" value="230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0" lower_limit="30.5" upper_limit="40.4"/>
                    <measurement group_id="O2" value="31.3" lower_limit="26.8" upper_limit="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feverishness or chills</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="337"/>
                    <count group_id="O2" value="341"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" lower_limit="20.0" upper_limit="22.0"/>
                    <measurement group_id="O2" value="21.2" lower_limit="20.3" upper_limit="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle or joint pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="300"/>
                    <count group_id="O2" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="21.6" upper_limit="26.7"/>
                    <measurement group_id="O2" value="24.0" lower_limit="21.6" upper_limit="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="293"/>
                    <count group_id="O2" value="308"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" lower_limit="23.2" upper_limit="30.5"/>
                    <measurement group_id="O2" value="26.6" lower_limit="23.0" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cough</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6623</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>6.8</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sore throat</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8184</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>1.8</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Headache</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9989</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>1.3</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Nasal congestion</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3706</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>1.7</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Feverishness or chills</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9973</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>-0.1</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Muscle or joint pain</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6760</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>-0.7</param_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fatigue</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4241</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>2.2</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Return to Preinfluenza Health Status in Participants Randomized to Baloxavir or Placebo</title>
        <description>Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health [for someone your age and your health condition]), and their health status every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score.
Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.</description>
        <time_frame>Initiation of study treatment up to Day 14</time_frame>
        <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo whose health status score at baseline was lower than the preinfluenza health status score and with available time to return to preinfluenza health status data.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Return to Preinfluenza Health Status in Participants Randomized to Baloxavir or Placebo</title>
          <description>Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health [for someone your age and your health condition]), and their health status every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score.
Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.</description>
          <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo whose health status score at baseline was lower than the preinfluenza health status score and with available time to return to preinfluenza health status data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="378"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.2" lower_limit="122.1" upper_limit="152.3"/>
                    <measurement group_id="O2" value="168.8" lower_limit="145.9" upper_limit="202.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</non_inferiority_desc>
            <p_value>0.0563</p_value>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>-39.5</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Return to Preinfluenza Health Status in Adults Randomized to Baloxavir or Oseltamivir</title>
        <description>Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health [for someone your age and your health condition]), and their health status every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score.
Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.</description>
        <time_frame>Initiation of study treatment up to Day 14</time_frame>
        <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, whose health status score at baseline was lower than the preinfluenza health status score and with available time to return to preinfluenza health status data.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Return to Preinfluenza Health Status in Adults Randomized to Baloxavir or Oseltamivir</title>
          <description>Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health [for someone your age and your health condition]), and their health status every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score.
Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.</description>
          <population>Participants in the intention-to-treat infection population, ≥ 20 years of age and assigned to baloxavir or oseltamivir, whose health status score at baseline was lower than the preinfluenza health status score and with available time to return to preinfluenza health status data.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.8" lower_limit="121.5" upper_limit="152.8"/>
                    <measurement group_id="O2" value="128.5" lower_limit="122.8" upper_limit="151.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7176</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Generalized Wilcoxon test</method>
            <method_desc>Generalized Wilcoxon test stratified by composite symptom scores at baseline (≤ 11 or ≥ 12) and region (Japan/Asia or Rest of the world).</method_desc>
            <param_type>Difference</param_type>
            <param_value>-0.6</param_value>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Influenza-related Complications in Participants Randomized to Baloxavir or Placebo</title>
        <description>The percentage of participants who experienced each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically confirmed pneumonia) as an adverse event after the initiation of the study treatment.</description>
        <time_frame>Initiation of study treatment up to Day 14</time_frame>
        <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Influenza-related Complications in Participants Randomized to Baloxavir or Placebo</title>
          <description>The percentage of participants who experienced each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically confirmed pneumonia) as an adverse event after the initiation of the study treatment.</description>
          <population>Participants in the intention-to-treat infection population assigned to baloxavir or placebo</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="456"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any complication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="2.0" upper_limit="5.6"/>
                    <measurement group_id="O2" value="4.3" lower_limit="2.1" upper_limit="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinusitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.2" upper_limit="2.2"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.1" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Otitis media</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.1" upper_limit="1.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronchitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.9" upper_limit="3.7"/>
                    <measurement group_id="O2" value="3.5" lower_limit="1.5" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.1" upper_limit="1.6"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.0" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Any Complications</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6728</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Influenza-related Complications in Adults Randomized to Baloxavir or Oseltamivir</title>
        <description>The percentage of participants who experienced each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically confirmed pneumonia) as an adverse event after the initiation of the study treatment.</description>
        <time_frame>Initiation of study treatment up to Day 14</time_frame>
        <population>Participants in the intention-to-treat infection population ≥ 20 years of age and assigned to baloxavir or oseltamivir.</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.</description>
          </group>
          <group group_id="O2">
            <title>Oseltamivir</title>
            <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Influenza-related Complications in Adults Randomized to Baloxavir or Oseltamivir</title>
          <description>The percentage of participants who experienced each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically confirmed pneumonia) as an adverse event after the initiation of the study treatment.</description>
          <population>Participants in the intention-to-treat infection population ≥ 20 years of age and assigned to baloxavir or oseltamivir.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="377"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any complication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="2.2" upper_limit="6.5"/>
                    <measurement group_id="O2" value="2.4" lower_limit="1.1" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinusitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.2" upper_limit="2.3"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Otitis media</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.1" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronchitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="1.1" upper_limit="4.5"/>
                    <measurement group_id="O2" value="1.6" lower_limit="0.6" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.1" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Any Complications</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2217</p_value>
            <p_value_desc>The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AEs)</title>
        <time_frame>From first dose of study drug to Day 22</time_frame>
        <population>All participants who received at least 1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Baloxavir</title>
            <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Oseltamivir</title>
            <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs)</title>
          <population>All participants who received at least 1 dose of study drug</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="610"/>
                <count group_id="O2" value="309"/>
                <count group_id="O3" value="513"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse events (AEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                    <measurement group_id="O2" value="24.6"/>
                    <measurement group_id="O3" value="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events (SAEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to withdrawal of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related adverse events (TRAEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="3.9"/>
                    <measurement group_id="O3" value="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TRAEs leading to withdrawal of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.3"/>
                    <measurement group_id="O3" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of treatment to Day 22</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Baloxavir</title>
          <description>Participants aged 20 to 64 years received 40 mg or 80 mg baloxavir (depending on weight) orally on Day 1 and placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
Participants aged 12 to 19 years received 40 mg or 80 mg baloxavir (depending on weight) on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants aged 20 to 64 years received placebo to baloxavir on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5. Participants aged 12 to 19 years received placebo to baloxavir on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Oseltamivir</title>
          <description>Participants aged 20 to 64 years received 75 mg oseltamivir orally BID on Days 1 to 5 and placebo to baloxavir on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="513"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="610"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="513"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="610"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="513"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="610"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="513"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="610"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="513"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="610"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="513"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shionogi Clinical Trials Administrator</name_or_title>
      <organization>Shionogi Inc.</organization>
      <phone>800-849-9707</phone>
      <email>Shionogiclintrials-admin@shionogi.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

